Sonography as a replacement for sialography for the diagnosis of salivary glands affected by Sjögren’s syndrome

Recently, it has been suggested that sonographic evaluation of the salivary glands is useful in the diagnosis of Sjögren’s syndrome. Kawamura et al and, more recently, Ariji et al, showed that descriptive and quantitative assessment of the salivary glands by sonography efficiently differentiated between diseased and normal glands in patients with Sjögren’s syndrome. They showed that the proposed sonographic gradings correlated well with the sialographic gradings. These findings suggest that sonography might be an alternative diagnostic tool for Sjögren’s syndrome.

Here, we attempted to determine whether sonography can take the place of sialography as an alternative technique for the assessment of salivary gland involvement in Sjögren’s syndrome. Sialography and sonography were performed on 294 patients who presented with sicca syndrome (171 positive and 123 negative for Sjögren’s syndrome). We diagnosed patients with Sjögren’s syndrome on the basis of the criteria of the European Community Study Group. Sonographic features characteristic of Sjögren’s syndrome are heterogeneous echogenicity with hypo- and hyperechoic signals throughout the affected gland (fig 1).

Table 1 shows the performance of each of the diagnostic criteria. Sialography performed best among the five diagnostic criteria—that is, sialography, functional tests (Saxon and Schirmer), and serological tests (SS-A and SS-B). Interestingly, when used instead of sialography, sonography provided a good performance, comparable with that of sialography (McNemar test, p=0.067). In contrast, the other diagnostic criteria did not perform as well as the two imaging criteria.

Logistic regression analysis was performed to identify diagnostic criteria that might be used as predictive indicators for differentiating between patients with and without Sjögren’s syndrome. Univariate logistic regression analysis showed that the six diagnostic criteria assessed (sialography, sonography, Saxon’s test, Schirmer test, SS-A, and SS-B) did correlate with a positive diagnosis of Sjögren’s syndrome, indicating that all six criteria, if used alone, could effectively predict the presence of Sjögren’s syndrome (table 1).

On multivariate analysis, however, only sialography and sonography showed significant correlations with a positive diagnosis of Sjögren’s syndrome (table 1); when sialography was used together with the functional and serological criteria, only sialography showed a significant correlation. If sonography was used instead of sialography, only sonography displayed a significant correlation with a positive diagnosis of Sjögren’s syndrome (table 1). Collectively, these findings suggest that the sonography performs as well as sialography in differentiating between parotid glands affected by Sjögren’s syndrome and normal glands. In contrast, the other diagnostic criteria did not perform as well as the two imaging criteria.

Some discrepancies were found between the diagnostic performance in the present study and that in previous studies. For example, Schirmer’s test in our study performed poorly compared with the performance reported by Vitali et al. SS-A and SS-B displayed high sensitivity and low specificity in our study, whereas low sensitivity and high specificity were found in the previous study. These inconsistencies may be due to the differences in patient groups or in techniques, or both. Despite these differences, the performance by sialography was similar, consistent with the notion that the imaging techniques, including sialography, provide reliable results in the diagnosis of Sjögren’s syndrome.

In conclusion, a diagnosis of Sjögren’s syndrome can be made on the basis of a wide range of diagnostic tests, and not merely on fixed combinations of these tests. Evaluation of salivary gland involvement contributes significantly to the performance of the criteria. Thus the availability of different imaging techniques, such as Doppler sonography and magnetic resonance imaging, to assess salivary gland involvement allows clinicians to classify patients with sicca syndrome correctly.

Table 1 Performance and logistic regression analysis of diagnostic criteria for Sjögren’s syndrome

<table>
<thead>
<tr>
<th>Diagnostic Criteria</th>
<th>Sialography</th>
<th>Sonography</th>
<th>Saxon</th>
<th>Schirmer</th>
<th>SS-A</th>
<th>SS-B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity [%]</td>
<td>87</td>
<td>76</td>
<td>70</td>
<td>59</td>
<td>83</td>
<td>88</td>
</tr>
<tr>
<td>Specificity [%]</td>
<td>98</td>
<td>94</td>
<td>71</td>
<td>57</td>
<td>56</td>
<td>42</td>
</tr>
<tr>
<td>Accuracy [%]</td>
<td>92</td>
<td>84</td>
<td>71</td>
<td>59</td>
<td>70</td>
<td>51</td>
</tr>
</tbody>
</table>

Univariate analysis

<table>
<thead>
<tr>
<th>Coefficient</th>
<th>SE</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Multivariate analysis

<table>
<thead>
<tr>
<th>Coefficient</th>
<th>SE</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NS, not significant.
Radiographs of the hands and feet were normal. There were slight erosions of the sacroiliac joints and of the symphysis pubis. The patient was treated with non-steroidal anti-inflammatory drugs (NSAIDs) and on several occasions with local injections of corticosteroids into the joint tears. For the psoriatic nails he took acitretine (Neotigason) at a daily dose of 20 mg, for 12 months, but the nail lesions did not improve. In view of the persistent nail deformities, the patient has been treated since January 2000 with sulfasalazine (the dose being progressively increased from 0.5 g daily to 2 g daily), in addition to NSAIDs. Three months later, the nail lesions started to recede and they disappeared progressively (fig. 1B); the improvement has persisted until now. Concomitantly, there was a marked improvement of the cutaneous lesions. Regarding the remaining lesions of psoriasis, it can be considered that sulfasalazine played a beneficial part in the pathological condition of our patient. Dermatological assessment of patients treated with sulfasalazine for PsA showed signs of cutaneous improvement compared with those receiving placebo. The series of Fert et al reports improved cutaneous lesions in as few as 3/15 patients treated with sulfasalazine and 1/15 patients receiving placebo. However, we could not find any indication of the evolution of possible simultaneous psoriatic nail lesions.

Treatment of PsA with cyclosporin or etanercept is effective for both joint and skin lesions of psoriasis,5 again no data about the outcome of psoriatic nail lesions were provided in these clinical studies. Our case report might be the occasion to draw the attention of rheumatologists to the possible beneficial effects of basic treatment such as sulfasalazine not only for PsA but also for treating psoriatic nails.

**References**


**Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease**

The high cost of IV immunoglobulins is often considered to be a disadvantage of this treatment. However, this does not take into account the benefits gained—for example, the savings achieved in the costs of corticosteroids and immunosuppressive drugs and, above all, the improvement in quality of life achieved through functional improvement, as noticed in inflammatory myopathies and Still’s disease.10 It is precisely to minimise the costs of IV immunoglobulin treatments and to enable patients to remain at home that we have developed the administration of IV immunoglobulins at home when sequential treatments are necessary.

Between January 1995 and March 2000 30 patients (18 women, 12 men) were enrolled, with a mean (SD) age of 44 (0.9) for the women and 51 (0.9) years for the men (range 21–74). All the patients had received the first two treatments in hospital to ascertain their tolerance. Patients mostly received Tymphéel (16 treatments), Endobuline (81 treatments), and Gammagard (three treatments). All the patients had a corticoiddependent or refractory autoimmune disease (mostly polymyositis, dermatomyositis, and adult onset Still’s disease).

The doses prescribed for each treatment were generally 2 g/kg. Treatments were carried out monthly and consisted of two days when performed in hospital and five days when performed at home. The average flow rate of the IV immunoglobulin perfusions performed at home was 10 g/h (extreme values: 30 min–4 h). The secondary effects of the treatments at home remained conventional and minor.

The efficacy of the IV immunoglobulin was described by the patients as very good (82%), good (17%), and nil (1%). The efficacy of the IV immunoglobulin was described by the senior doctor as very good (53%), good (30%), and nil (17%). Evaluation of the efficacy described by the patients themselves was based on purely functional criteria (general condition, pain, mobility, activities of daily living, sleep, and treatment schedule). The patients themselves considered their quality of life to have improved, and their mobility and activities of daily living to have been better than before the treatment. The duration of treatment varied according to the diagnosis and the patients’ personal situation and needs, and the treatments at home were continued until remission of the disease or at the request of the patient. The number of treatments administered in hospital and at home was used to calculate the cost of the treatments. The average cost of one treatment at home was €500 (range 300–700), and the estimated annual cost of treatment at home was €30 000 (range 20 000–40 000).

**References**


**References**

muscular deficit, etc.), which explains the difference between the two evaluations. Cases where the IV immunoglobulin resulted in a reduced use of corticosteroids, or cases where IV immunoglobulins made it possible to avoid using immunosuppressive drugs were regarded as a success by the senior doctor, whereas patients did not necessarily have the same impression.

The 23 patients (77%) who said they had benefited from the IV immunoglobulin treatments at home gave the following reasons: better comfort (n=12), presence of next of kin (n=10), more occupation (n=6), time gain (n=5), better mood (n=3), maintaining activities (n=3), avoiding repeated trips to the hospital (n=3), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital (n=3), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital gave the following reasons: better monitoring, less trouble (IV immunoglobulin collected at the pharmacy and at home).

The mean cost of a treatment in hospital was $2701 against $2471 for a treatment at home. Collection of tubes, needles, and percutaneous insertion of an IV were quicker at home, whereas patients did not necessarily have the same impression.


differentiation of the two evaluations. Cases where the IV immunoglobulin resulted in a reduced use of corticosteroids, or cases where IV immunoglobulins made it possible to avoid using immunosuppressive drugs were regarded as a success by the senior doctor, whereas patients did not necessarily have the same impression.

The 23 patients (77%) who said they had benefited from the IV immunoglobulin treatments at home gave the following reasons: better comfort (n=12), presence of next of kin (n=10), more occupation (n=6), time gain (n=5), better mood (n=3), maintaining activities (n=3), avoiding repeated trips to the hospital (n=3), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital (n=3), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital gave the following reasons: better monitoring, less trouble (IV immunoglobulin collected at the pharmacy and at home).

The mean cost of a treatment in hospital was $2701 against $2471 for a treatment at home. Collection of tubes, needles, and percutaneous insertion of an IV were quicker at home, whereas patients did not necessarily have the same impression.

Table 1  Evaluation of the cost of at home IV immunoglobulin treatments (n=277) and comparison with the theoretical cost in hospital

<table>
<thead>
<tr>
<th>IV immunoglobulin</th>
<th>Theoretical cost in hospital</th>
<th>Effective cost at home</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cost for 277 treatments</td>
<td>Savings achieved for 277 treatments</td>
<td></td>
</tr>
</tbody>
</table>

1. Theoretical cost in hospital: $2955 (deduction on drug budget) + $605 (deduction on small equipment budget) + $41 (Nursing) = $3601
2. Effective cost at home: $2363 (15% of retrospective cost) + $41 (Nursing) = $2404
3. Savings achieved for 277 treatments: $3601 - $2404 = $1197

*In France when a drug is retroceded by a hospital pharmacy, it is invoiced 15% higher, the difference being paid to the hospital administration to cover the management and traceability costs.

References

Elastofibroma dorsi

Elastofibroma is a rarely diagnosed benign fibroproliferative lesion which occurs most commonly in the periscapular region of middle aged to elderly women. Recognition of the lesion is important as the differential diagnosis includes other benign and also

Table 2  Home IV immunoglobulin infusion guidelines for patients with autoimmune disease

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Need for a defined diagnosis</td>
<td></td>
</tr>
<tr>
<td>2. Presence of rational physiopathological basis that could “legitimise” the use of IV immunoglobulin</td>
<td></td>
</tr>
<tr>
<td>3. Senior hospital prescription</td>
<td></td>
</tr>
<tr>
<td>4. Respect of the contraindication of home IV immunoglobulin programme: coronaryopathy, insufficiency or ischaemic cardiopathy, recent stroke, nephropathy, uncontrolled hypertension, thrombosis of the perfused vein, hypersensitivity reaction after the first or second hospital infusion</td>
<td></td>
</tr>
<tr>
<td>5. More than one hospital based infusion before infusion at home to assess the tolerance</td>
<td></td>
</tr>
<tr>
<td>6. Average flow rate of IV immunoglobulin no quicker than 10 g per two hours</td>
<td></td>
</tr>
<tr>
<td>7. Collaboration with a home care organisation for visiting nurses and for collection of tubing and used bottles</td>
<td></td>
</tr>
</tbody>
</table>
Elastofibroma dorsi, first described in 1961, is a benign, slow growing, mesenchymal soft tissue lesion. It usually occurs in active subcutaneous compartments, head, abdominal and thoracic cavities. Clinically, over 50% of subjects are asymptomatic and may present with a painless swelling; approximately 25% present with a clicking sensation when the arm is moved, while fewer than 10% present with pain. The pain is described as a dull ache of gradual onset, around the posterior aspect of the shoulder over the scapula, which was worse on movement of the arm. There was no weakness. On the preceding four months the patient had noticed a swelling below the inferior angle of the right scapula which would appear and disappear with movement of the arm. The patient had no other medical history or relevant family history.

On examination there was a full range of movement of both shoulders and neck with no wasting or neurological signs. Pain was reproduced around the right shoulder when the arm was circumducted. In this position a firm, poorly circumscribed, and minimally mobile mass of 5x5 cm was apparent under the inferior angle of the right scapula which the patient had noticed a swelling below the shoulder and scapula. Subsequent magnetic resonance imaging (MRI) showed a poorly defined mass (long arrow) with areas of high signal within. The mass lies between the serratus anterior (short arrow) and the thoracic cage (C), L, latissimus dorsi.

Figure 1 Magnetic resonance image (T1 weighted axial) of the right infrascapular region showing a poorly defined mass (long arrow) with areas of high signal within. The mass lies between the serratus anterior (short arrow) and the thoracic cage (C). L, latissimus dorsi.

Local excision is the best treatment. Recurrence has not been reported.

We conclude that elastofibroma should be considered in the differential diagnosis of subscapular pain. Although an uncommon lesion with a variable clinical presentation, the site and MRI appearances are characteristic. Awareness of the benign nature avoids unnecessary surgery and reassures a symptomatic patient.

D Pyne, R Mootoo, A Bhanji
Rheumatology Department, Homerton Hospital, Homerton Row, London E9 6SR, UK
S Amin
Radiology Department, Homerton Hospital
Correspondence to: Dr R Mootoo

References

Olecranon bursitis due to Candida parapsilosis in an immunocompetent adult

Septic bursitis (SB) mainly affects the olecranon and patellar bursa. Subcutaneous localisation predisposes to trauma and may subsequently lead to infection. Most cases of SB are related to the subject's occupation (roofing, gardening, plumbing), but surgical interventions (aspiration, intraarticular injection) are among other probable causes. Bacteria account for most cases, Staphylococcus aureus being the most commonly found (80%).1,2 Fungal isolation is quite rare and always associated with immunosuppression or debilitating conditions,3 but some species of Candida, Cryptococcus, Penicillium, and Sporothrix schenckii have been described.4 These atypical organisms usually develop in a late indolent pattern, and a delay in diagnosis and treatment may lead to considerable difficulties in eradication of infection. We report a case of SB caused by Candida parapsilosis in a previously healthy man, with no underlying disease or any risk factors, including HIV infection, who probably acquired joint infection at the hospital secondary to local steroid injection.

Case report
A 32 year old man with a one month history of mild inflammation of the right elbow presented to our hospital on 19 May 2000. He had
an unremarkable past medical history, which did not include any toxic habits or recent trauma. Bursal aspiration showed that the synovial fluid had inflammatory characteristics (leucocyte count 4.9 x 10^3 cells/l (54% neutrophils), and a glucose level of 3.8 mmol/l), but there were no crystals and a fluid culture was negative. A diagnosis of olecranon bursitis was established, and conservative management (steroid injections) was decided on. Bursal effusion was repeated over the next four days, so a further aspiration was carried out and local injection with triamcinolone acetate (20 mg) was given. However 24 days later the pain was not improved and swelling of the elbow recurred. Laboratory synovial findings showed a leucocyte count of 15.7 x 10^3 cells/l (60% neutrophils) and a low glucose level (0.8 mmol/l). Culture yielded a few colonies of Candida spp, but antifungal treatment was not started because it was considered that this might be caused by contamination. One month later (28 July), the patient presented to the emergency room owing to development of a new, extremely painful episode of bursitis. After joint aspiration, a steroid injection was again given, but this time the fluid culture was not carried out.

On 1 August clinical symptoms persisted. Physical examination showed an increase in the size of the olecranon bursa. The patient had never presented with fever, arthralgias, or any general complaints. Laboratory studies, including a test for antibodies to HIV, were normal (negative). Magnetic resonance imaging was performed showing multisepate bursitis; the adjacent structures were normal. A removal of 10 ml bursa fluid again yielded a positive culture for Candida that was later identified as C parapsilosis (Madrid, National Centre for Microbiology). Antifungal sensitivity testing showed a minimal inhibitory concentration for amphotericin B of 1 mg/l, 5-fluorocytosine 0.25 mg/l, fluconazole 0.23 mg/l, itraconazole 0.03 mg/l, and ketoconazole 0.015 mg/l. By the end of August, oral fluconazole was started at a dose of 400 mg/day for seven days, and then 200 mg daily. Recovery was slow and the patient needed repeated drainage. As follow up cultures were still positive, on 27 September it was decided to carry out surgical debridement with complete excision of the olecranon bursa. This material was not cultured, but histopathological analysis was performed demonstrating pseudohyphae structures, without granulomatous reaction or foreign bodies. After bursectomy, the patient continued fluconazole treatment (same maintenance dose) for six weeks more. Six months later he is completely asymptomatic.

Infection of superficial bursae (olecranon, prepatellar, and infrapatellar) is generally associated with different occupations or physical activities. Local trauma may predispose micro-organisms to penetrate by the transcutaneous route. Similarly, intrabursal steroid injection, a habitual therapeutic procedure, may lead to infection. Weinstein et al noted that development of infection after this procedure occurred in 12% of a series of cases. Most frequently bacteria cause infections, but unusual pathogens like fungi have also been described. Candida septic bursitis is extremely rare. After a thorough review of the Medline database (from 1966 to January 2001) using medical subject headings, and keyword searches that included “septic bursitis” and “Candida septic bursitis,” we found only two reports. Two caused by C albicans, two by C tropicalis, and another one by C lusitaniae (table 1). Characteristically, in all the cases, and in the present report, different risk factors or underlying diseases were found. Four cases were caused by haematogenous spread and two induced by direct penetration, including our case. The olecranon bursa was affected in three cases, including the present report. C parapsilosis is a well known cause of arthritis that has been described secondary to systemic dissemination in intravenous drug users, and also by direct inoculation secondary to intrarterial injections. It is not strongly associated with invasivecompromised hosts, but rather with invasive procedures or prosthetic devices. More recently C parapsilosis has emerged as an important nosocomial pathogen. This is the Candida species that is most commonly isolated from the hands of healthcare workers. In contrast with other Candida species, colonisation with C parapsilosis rarely occurs before the onset of invasive infection, suggesting an exogenous source of infection.

Appropriate antifungal drugs to treat Candida infections are available, but appropriate drug levels in osteoarticular structures are difficult to achieve. So for successful treatment of this infection, surgery is sometimes required. Half of the patients with Candida SB reviewed needed surgery for complete resolution (table 1). We would like to summarise several aspects of the present report: Firstly, steroid injection must be carefully prescribed in order to avoid probable side effects like infection. Secondly, most cases of Candida SB are produced by haematogenic spread, secondary to disseminated infection, whereas the present case was almost certainly through direct inoculation. Thirdly, isolated C parapsilosis was neccted at the start so that antifungal treatment was delayed, leading to the need for surgery. We consider that the diagnostic delay together with a rather low maintenance dose of fluconazole were critical for the very slow resolution of the infection; probably 400 mg/day would have been more suitable for an infection in a deep compartment.

Because unusual micro-organisms are difficult to recognise and anti-inflammatory drugs may mask the symptoms, a higher degree of awareness is necessary to achieve prompt diagnosis and successful treatment. Nevertheless, special care must be taken to avoid complicating side effects in iatrogenic manipulations, so preventive measures to reduce the incidence of infection must never be omitted.

M Jiménez-Palop, M Corteguera
Unit of Rheumatology, Hospital Nuestra Señora de S Terranos, Avila, Spain
R Ibáñez
Unit of Microbiology, Hospital Nuestra Señora de S Terranos
Serrano-Heranz
Unit of Infectious Diseases, Hospital Nuestra Señora de S Terranos
Correspondence to: Dr R Serrano-Heranz, Encarnación 14, Chalet 18, 05005 Avila, Spain; reginash@interbook.net

References

Table 1 Main clinical features of candida bursitis

<table>
<thead>
<tr>
<th>Case [ref]</th>
<th>Age/sex</th>
<th>Candida strains</th>
<th>Localisation</th>
<th>Underlying disease</th>
<th>Probable source</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 [3]</td>
<td>73/M</td>
<td>C albicans</td>
<td>Subacromial</td>
<td>SLE/steroids</td>
<td>Candidaemia</td>
<td>AMB</td>
<td>Cure</td>
</tr>
<tr>
<td>2 [5]</td>
<td>77/M</td>
<td>C tropicalis</td>
<td>Olecranon</td>
<td>Bladder carcinoma</td>
<td>Candidaemia</td>
<td>AMB + surgery</td>
<td>Cure</td>
</tr>
<tr>
<td>3 [6]</td>
<td>48/M</td>
<td>C tropicalis</td>
<td>Popliteal</td>
<td>Lymphoma/immunosuppressive drugs</td>
<td>Candidaemia</td>
<td>AMB + surgery</td>
<td>Cure</td>
</tr>
<tr>
<td>4 [7]</td>
<td>64/M</td>
<td>C albicans</td>
<td>Popliteal</td>
<td>Alcoholism/steroids, antibiotics</td>
<td>Candidaemia</td>
<td>AMB, ketoconazole</td>
<td>Cure</td>
</tr>
<tr>
<td>5 [8]</td>
<td>59/F</td>
<td>C lusitaniae</td>
<td>Olecranon</td>
<td>SLE, diabetes, asthma/steroids, immunosuppressive drugs</td>
<td>Superficial trauma</td>
<td>Fluconazole, 5-FC</td>
<td>Failure</td>
</tr>
<tr>
<td>6 [CR]</td>
<td>32/M</td>
<td>C parapsilosis</td>
<td>Olecranon</td>
<td>None</td>
<td>Steroid injection</td>
<td>Fluconazole + bursectomy</td>
<td>Cure</td>
</tr>
</tbody>
</table>

CR, current report; AMB, amphotericin B; SLE, systemic lupus erythematosus; 5-FC, 5-fluorocytosine.
Prevalence of allergic respiratory diseases in patients with RA

The balance between Th1 and Th2 cell activity is crucial in many autoimmune diseases.

It is considered crucial in many autoimmune diseases. The balance between Th1 and Th2 cell activity is important in many autoimmune diseases such as RA, and the biological importance of the Th1/Th2 paradigm has been emphasised. We evaluated the prevalence of atopic respiratory diseases in 126 consecutively observed adult patients with RA (mean age 53.8 ± 14.9 years, 95% female) by a trained allergologist.

Skin prick tests were made according to the EAACI guidelines, with a panel including the most common airborne allergens of our area. A diagnosis of allergic rhinitis was made in 35 patients (28%), 25 of whom had also asthma. The diagnosis was based on a suggestive clinical picture associated with the positivity of skin prick tests. Seven of 21 patients had symptoms of asthma and 3/21 had undergone specific immunotherapy before the onset of RA symptoms. In 5/21 patients allergic respiratory symptoms had started before the onset of RA symptoms. In 5/21 patients atopic symptoms had totally disappeared by the time of this study.

Patients with RA and associated atopic disease did not differ from other patients with RA in the following characteristics: (a) sex (76.2% female vs 73.2%); (b) positivity of rheumatoid factor (71.4% vs 63.8%); (c) presence of subcutaneous noduli and/or other articular manifestations (14.3% vs 21.9%); (d) functional class according to the ACR revised criteria (class I-I: 64% vs 60%); (e) current treatment with two or more disease-modifying antirheumatic drugs in combination (57.1% vs 60.9%); (f) current steroid treatment (57.1% vs 53.4%). Notably, most patients from both groups (90.9% vs 76.8%) were taking steroids at a low dose—namely, not more than 5 mg daily of prednisone, when they were evaluated for this study.

Patients with atopic diseases were younger (mean age 53.8 ± 15.7) and had a shorter average duration of RA (4.5 ± 9.7 years) than those without.

We found a rather high prevalence of allergic respiratory diseases in our patients with RA (16.6%), comparable with that expected in the general population. Moreover, the presence of atopic disease did not seem to influence the severity of RA.

The difference between our data and other reports may be due to the methods used to determine the prevalence of atopic diseases. Those other studies started from the administration of standardised questionnaires to patients with RA and this method might have caused an underestimation of atopic symptoms. Conceivably, prolonged steroid treatment, as well as the systemic symptoms and disability associated with RA, may often cause occult symptoms of rhinitis and asthma that only emerge at deeper analysis.

In conclusion, our data question the hypothesis of a mutual antagonism of RA and atopy, suggesting caution in interpreting previous data and confirming that things are often not as simple as they can seem at first glance.

References


Henoch-Schönlein purpura: a possible complication of hepatitis C related liver cirrhosis

Henoch-Schönlein purpura (HSP) is a systemic small vessel vasculitis predominantly affecting children and, less commonly, adults. Classical HSP includes a tetrad of palpable purpura, arthritis, abdominal pain, and haematuria. Symptoms may be limited to one or two of the four criteria in the tetrad (87% sensitivity and specificity). Gastrointestinal disease has been recorded in up to 82% of adult patients in one series and is usually self limiting with colicky abdominal pain, but may progress to ischaemic bowel perforation.2

We present the case of a 63 year old man with IgA vasculitis, probably HSP conformed by undiagnosed hepatitis C related liver cirrhosis. He was admitted to the hospital with a two week history of dyspepsia, malaise, cough, fever, chills, myalgias, one day of a non-bloody chymotheomous rash on his legs, and an ileus. His hepatitis C antibody was positive. Table 1 shows the results of other laboratory studies.

Cultures of cerebrospinal fluid, blood, and urine were negative. A colonscopy was non-diagnostic.

Leucocytoclastic vasculitis was confirmed by skin biopsy, and direct immunofluorescence staining was positive for IgA deposits consistent with HSP (fig 1).

Treatment with high dose (1 mg/kg/day) intravenous corticosteroids was started. A second CT scan 4 days after admission showed portal hypertension, a small cirrhotic liver, small spleen, omental and perilapatic varices, an atrophic pancreas, and modest ascites. The purpuric lesions and ileus improved, however, on day 4 he became tachycardic and developed a tender abdomen. A second CT scan showed massive ascites, a partial superior mesenteric vein thrombosis, thickening, and focal and nodular irregularities throughout the small bowel (probable ischaemia), and pneumoperitoneum. Blood cultures disclosed sepsicaemia with Bacteroides fragilis. His clinical course rapidly deteriorated and he died on day 8.

There are two previous case reports of the association between HSP and hepatitis C.1 10 The diagnosis of HSP is relatively frequent, but most likely, given palpable purpura, haematuria, abdominal pain, and a skin biopsy demonstrating IgA complexes (fig 1). However, the possibility of hepatitis C associated IgAL/M mixed cryoglobulinaemia cannot be ruled out, despite a negative cryoglobulin screen on two occasions. In this patient an IgA mediated vasculitis may have been the nidus for thrombus formation and abdominal catastrophe.

The role of liver cirrhosis in the development of HSP is intriguing. Patients with cirrhosis may develop HSP as a consequence of defective liver metabolism of IgA circulating immune complexes (CICs), resulting in tissue deposition, although this is known to occur without overt vasculitis.1 10 Adult and paediatric HSP differ in the incidence and severity of renal involvement, with nephropathy and progression to renal insufficiency being greater in adults with HSP1 10 which is associated with a poor outcome.2 Gastrointestinal manifestations vary widely and include abdominal pain, nausea/vomiting, intestinal haemorrhage and, rarely, perforation.1 2 10 11 There have been no large clinical trials in adults with complicated HSP. Corticosteroids used in the hope of children have shown to relieve symptoms,9 but fail to deal prospectively with the prevention of colicky abdominal pain.10 Adults respond favourably to corticosteroids and may be managed with short courses of treatment,10 but corticosteroids may also mask severe abdominal catastrophe.

Several important points can be learnt from this case report:

Although nephritis is the most important long term prognostic factor in HSP, short term, gastrointestinal disease can lead to death despite early therapeutic intervention.

Liver cirrhosis secondary to hepatitis C may precipitate development of HSP or mixed cryoglobulinaemic vasculitis through the de facto metabolism of CICs.

The increasing incidence of hepatitis C related liver disease world wide, the association of these diagnoses and the clinical implications should be considered more often.

Acknowledgment

We thank Drs Karen Stout, Brett Sheppard, Amy Howard, and Sandhya Venugopal for their participation in, and discussions about, this case.

www.annrheumdis.com

Author Details

G Provenzano, G Donato Azienda Ospedaliera “Villa Sofia – CTO”, Divisione di Malattie dell’Apparato Toracico, Palermo, Italy

G Broi, F Rinaldi Azienda Ospedaliera “V. Cervello”, Divisione di Medicina II, Palermo, Italy

Correspondence to: Dr G Provenzano, Via Massimo d’Azeglio No 2, 90143 Palermo, Italy; giuseppe.provenzano01@tin.it

PostScript 281

Table 1 Significant laboratory values on the day of admission

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient’s values</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin (g/l)</td>
<td>114</td>
<td>135–175</td>
</tr>
<tr>
<td>White blood cell count (×10³/l)</td>
<td>14000</td>
<td>3.4–10</td>
</tr>
<tr>
<td>Platelet count (×10⁹/l)</td>
<td>130</td>
<td>0.15–420</td>
</tr>
<tr>
<td>Complement C3 (mg/l)</td>
<td>400</td>
<td>880–2030</td>
</tr>
<tr>
<td>Complement C4 (mg/l)</td>
<td>&lt;100</td>
<td>160–470</td>
</tr>
<tr>
<td>Serum creatinine (µmol/l)</td>
<td>88</td>
<td>70–110</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>99</td>
<td>35–105</td>
</tr>
<tr>
<td>Aspartate aminotransferase (U/l)</td>
<td>40</td>
<td>11–32</td>
</tr>
<tr>
<td>Alanine aminotransferase (U/l)</td>
<td>39</td>
<td>5–30</td>
</tr>
<tr>
<td>Lactate dehydrogenase (U/l)</td>
<td>176</td>
<td>110–205</td>
</tr>
<tr>
<td>Total bilirubin (µmol/l)</td>
<td>38</td>
<td>4–20</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>15</td>
<td>36–52</td>
</tr>
<tr>
<td>Urine analysis (RBC/HPF)</td>
<td>20</td>
<td>0–3</td>
</tr>
<tr>
<td>ANA titre</td>
<td>1/40</td>
<td>&lt;1/40</td>
</tr>
</tbody>
</table>

RBC/HPF, red blood cells/high power field; ANA, antinuclear antibody.

Figure 1 Immuno fluorescence staining of a skin biopsy from a purpuric lesion. Direct immuno fluorescence study showing granular deposition of IgA in the walls of superficial dermal blood vessels, a characteristic finding in Henoch-Schönlein purpura.

Severe aortic regurgitation in RF positive polyarticular JIA

An 18 year old girl of Moroccan origin with a clear medical history was transferred to the Netherlands in February 1989 because of a two year history of untreated polyarthritis. The disease had pursued a rapidly destructive course, resulting in contractures and ankylosis of hips, knees, shoulders, and elbows and small joint deformation. A diagnosis of juvenile idiopathic arthritis (JIA) polyarticular type, functional class IV was made. No nodules were present. Laboratory analysis at that time showed borderline positive serum rheumatoid factor (RF) 30 IE/ml. Tests for antinuclear antibodies and HLA-B27 were negative. Treatment was started with intensive physiotherapy and intramuscular gold, the latter being replaced by sulfasalazine because of proteinuria. In 1990 she was treated for a unilateral uveitis. In 1992 her right elbow was replaced. Until 1993 cardiac examination showed no murmurs and chest roentgenogram was normal.

In November 1995 she was admitted because of a six month history of progressive respiratory distress and increasingly frequent attacks of angina pectoris. Her heart rate was 84 beats/min with a blood pressure of 160/0 mm Hg. A grade 3/6 systolic ejection murmur that radiated into the ascending aorta was heard over the cardiac apex as well as a grade 3/6 diastolic decrescendo murmur over the left sternal border. A pericardial friction rub was not present. Examination of the carotid arteries disclosed a murmur and palpable thrill on both sides. An electrocardiogram showed left ventricular hypertrophy and the chest radiograph slight cardiomegaly. An echocardiogram demonstrated left ventricular dilatation (65 mm; normally <55 mm) and an abnormally thickened aortic valve. Colour Doppler echocardiography showed severe aortic regurgitation, a pressure gradient over the aortic valve (maximum pressure gradient 38 mm Hg, mean gradient 24 mm Hg), and diastolic back flow in the abdominal aorta. The diagnosis aortic valve insufficiency and secondary angina pectoris was made.

She underwent surgical replacement of her aortic valve with a Medtronic Hall prosthetic valve. No 21. The postoperative course was uneventful. Pathological evaluation of the excised strongly thickened and fibrotic trileaflet aortic valve was performed.

Microscopic findings in one of the rheumatoid leaflets showed yellowish tissue with lymphoplasmocellular infiltration and some polymorphonuclear cells around two areas of fibrinoid necrosis surrounded by a polysial of histiocytes (figs 1 and 2). These findings are similar to the description of a developed typical rheumatoid nodule.

At follow up after four years the aortic valve prosthesis still functions well and the patient has no cardiac signs and symptoms.

To our knowledge, this case is the first illustrated report of typical rheumatoid nodules found in an aortic valve removed owing to aortic valve insufficiency in a patient with polyarticular JIA. Our patient never had any nodules on other locations. Valvular disease is rare in patients with JIA and consists of valvulitis with a substrate with non-specific...
changes of fibrosis and necrosis. Valvular involvement has been described in patients with all types of JIA, the aortic valve being most commonly affected.® Valvular disease is associated with severe destructive articular disease.®

Furthermore, our case report confirms the possibility of successful mechanical aortic valve replacement in a case of severe progressive aortic valve insufficiency and secondary angina pectoris in a patient with polyarticular JIA.

We recommend regular cardiac appraisal as part of the routine assessment of every patient with JIA. Whenever cardiac murmurs are detected in these patients, echocardiographic assessment should be considered, because if there is valve insufficiency the cardiac function may deteriorate and cardiac surgery may be needed.

Acknowledgments

We are grateful to Dr J van der Meulen, cardiologist, for allowing us to report on her patient. Dr AC van der Wal, pathologist, for his pathology specimen, and Dr JC M van der Harst, surgical surgeon, for the surgical description and to Dr M van der Deij, cardiologist, for his insight.

PostScript

The presenting symptoms (girdles bilateral and symmetrical stiffness and pain) are accompanied by systemic features (fatigue, weight loss, raised ESR) and the marked improvement after prednisone confirm the diagnosis of polyarthritis rheumatica.

As far as we know this is the first report of pericardial tamponade requiring pericardial drainage in this disease.

A Brucato, G Brambilla
Divisione Medica "Brena", Ospedale Niguarda Ca' Granda, Milan, Italy

Correspondence to: Dr G Brambilla, Divisione Medica "Brena", Via Mamei 46, 1219, Milan, Italy; Brambilla@tiscalinet.it

References


2. Goossens et al reported on a patient in whom a remission of Behçet's syndrome was induced with tumour necrosis factor (TNF) blocking treatment. We would like to add our experience in a patient with Behçet's disease associated with rheumatoid arthritis (RA), treated with infliximab (Remicade).

A 47 year old male patient, born in Morocco, living in Israel, was diagnosed 14 years ago with Behçet's disease. His complaints included periorbital swelling, mouth ulcers, moderate fever, asthenia, and persistent high erythrocyte sedimentation rate and C reactive protein. In parallel, the patient reported recurrent buccal and genital ulcers two to three times a month with papulopustular skin lesions on the feet. HLA-B5 (51) was positive. There was no eye involvement. A diagnosis of Behçet's disease associated with erosive, seropositive RA was suggested. The patient was treated with sulfasalazine and colchicine without improvement; steroid treatment with auranofin was added. The disease worsened poorly controlled, with progressive erosions in hands, knees, and feet. Later, pulse steroids, methotrexate, azathioprine, and cyclosporin were added serially, either singly or in combination.

In subsequent years he became dependent on steroids and never achieved complete remission. In December 2000 the patient was admitted to hospital with severe active polyarthritis, flexion contractures of the elbows, and an especially swollen left knee with Baker's cyst and severe erosive disease. The patient additionally had buccal and penile ulcers. Because of the lack of response to conventional treatment we decided to treat him with infliximab (Remicade; Schering), a chimeric IgG monoclonal antibody directed against TNF. He received 300 mg intravenously (3 mg/kg) at intervals of two weeks, six weeks, and then every eight weeks. Two weeks after the first infusion the ulcers of mouth, penis, and other skin lesions were already considerably smaller and later disappeared. The polyarthritis improved considerably, except for the left knee, which required total replacement. Infliximab was given with continued colchicine and azathioprine. Our case, as in Goossens' report, suggests that infliximab may have a beneficial therapeutic effect in microvascular and cutaneous lesions as well as...
Fatigue and immune activity in Sjögren’s syndrome

Despite major desiccation of mucous membranes in Sjögren’s syndrome (SS), fatigue is often experienced by patients as the most disabling complaint. Unfortunately, there is no proper treatment available to combat the fatigue in SS. Beside a variety of somatic and non-somatic conditions, increased immune activity has been implicated as a cause of fatigue in autoimmune diseases. If responsible for fatigue in SS, it could serve as a treatment target. The purpose of this study was, therefore, to examine the relation between fatigue and immune variables in SS.

Thirty six consecutive patients with primary SS visiting our outpatient departments participated in this study. Two control groups were used: a group of 18 patients diagnosed with secondary SS, and a group of 30 non-medicated healthy controls. Diagnoses were based on the revised European criteria. Control groups were matched for age and sex. Disease duration or treatment did not differ significantly between patients with primary and secondary SS. Patients with other chronic diseases were excluded from the study. The Dutch Fatigue Scale (DFUS) was used to quantify fatigue. This validated questionnaire poses nine questions about different aspects of fatigue (Table 1). Because depression is frequently observed in SS, a standardised psychiatric questionnaire (SCL-90) was used to rule out this potential confounding variable for fatigue. Immunological activity was evaluated by assessing rheumatoid factor, antinuclear antibodies, presence of anti-SS-A and anti-SS-B, levels of immunoglobulins (IgG, IgM, and IgA), haemoglobin levels, leucocytes, thrombocytes, erythrocyte sedimentation rate, and C reactive protein (CRP). After preliminary analysis using correlation tests, the best model to explain fatigue was calculated by using multiple regression with forward selection (SPSS version 8.0). Independent Student t tests were used to compare the studied groups.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Dutch Fatigue Scale. Each item is scored on a 1 to 4 point scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Listlessness</td>
</tr>
<tr>
<td>2.</td>
<td>Perceived need for additional energy to finish required tasks</td>
</tr>
<tr>
<td>3.</td>
<td>Verbalisation of an unrelenting and overwhelming lack of energy</td>
</tr>
<tr>
<td>4.</td>
<td>Inability to restore energy, even after sleeping</td>
</tr>
<tr>
<td>5.</td>
<td>Increase in rest requirements</td>
</tr>
<tr>
<td>6.</td>
<td>Decreased libido</td>
</tr>
<tr>
<td>7.</td>
<td>Inability to maintain usual routine</td>
</tr>
<tr>
<td>8.</td>
<td>Impaired ability to concentrate</td>
</tr>
<tr>
<td>9.</td>
<td>Decreased performance</td>
</tr>
</tbody>
</table>

Fatigue was equally raised in patients with both primary and secondary SS, and differed significantly from that of healthy controls. Twenty one (58%) patients with primary SS scored “high” or “very high” out of the six categories for depression according to the SCL-90 criteria. These depression scores did not significantly differ from the scores in secondary SS patients. Further analysis showed that 79% of the fatigue in patients with primary SS could be explained by depression, total level of immunoglobulins, and thromboocyte counts (p<0.001). Both depression and thromboocyte counts showed a significant positive correlation, whereas levels of immunoglobulins showed a negative correlation.

Though targeting as a treatment target, the immune and inflammatory variables failed to predict fatigue satisfactorily in primary SS. Levels of immunoglobulins showed, surprisingly, a significant negative correlation. Thromboocyte counts showed a significant positive correlation. Although increases in thromboocytes follow the acute phase reaction, no significant correlation between thromboocyte counts and CRP levels were found. A chance association between fatigue and thromboocyte counts as well as immunoglobulin levels seems thus possible. Therefore, the intriguing question whether immune or inflammatory activity is a causative factor of chronic fatigue in SS remains unravelled. Because no difference in fatigue was found between patients with primary and secondary SS, the presence of another autoimmune disease appears to have no additional effect on the amount of fatigue in SS. In agreement with findings of previous studies, a significant relation was found between the degree of fatigue and the level of depression in patients with primary SS. It is concluded that none of the laboratory variables reflecting immune activity predict fatigue satisfactorily in primary SS. Signs of depression, as present in most of the patients with primary SS, proved to be the most relevant cause of their exhausting fatigue. Therefore we recommend including a psychosomatic approach in the treatment of fatigue in primary SS.

---

Glucoorticoids


People are bound to think: Oh no! Is yet another book about drugs that we are using successfully every day really necessary? Well, the answer to this question is: Yes, it is! More than 50 years after the discovery of the glucocorticoids, updates are necessary to establish Milestones in drug therapy (the title of the series published by Birkhäuser). Sometimes unnoticed by all who use glucocorticoids, new, not always spectacular, but still significant knowledge has been gained about these vital drugs and how they should be administered. The authors try to put this across in a readable form, which means that known information is recapitulated concisely and new information is included. A very good example are the chapters that deal with the basic mechanisms of action. However, the only real criticism also applies at this point: some comments are redundant and tighter editing would have improved individual contributions.

Renowned authors reflect upon the most important facets of treatment with glucocorticoids. These facets include the history as well as basic biology, the development of synthetic compounds, extensive discussions about the glucocorticoid receptor, the dynamics of cytokine and other gene regulations by glucocorticoids, the interrelationship between exogenous and endogenous steroids, and a clinical section which deals with the use of steroids in asthma, arthritis, and inflammatory bowel disease. Allan Munck, one of the...
wise men of steroid research, describes the history of the glucocorticoids graphically and in detail. He has enriched research in this field with significant contributions since the beginning of the 1960s and now looks back amusingly and expressively on the past decades. Luca Parente’s contribution ranges from naturally occurring to synthetic glucocorticoids and their effects in the organism. The sections that deal with the desired anti-inflammatory/immunomodulatory effects and adverse reactions give a valuable overview.

A few chapters should be highlighted that are of particular interest for both rheumatologists and clinical immunologists. That on molecular and cellular aspects of cytokine regulation by glucocorticoids has been prepared very carefully from a didactic point of view. It not only describes T cell activation and the effects of glucocorticoids thereon, but also provides useful information for an understanding of the function and regulation of cytokines. It is recapitulated that the central therapeutic effects of glucocorticoids are ultimately the inhibition of the synthesis of interleukin 2 and interleukin 6; glucocorticoids influence the transcription of around 1% of all genes! However, they also have an influence on the translational and post-translational mechanisms by which proteins are synthesised, processed, and exported from cells. This fact applies, in particular, to the influence on cytokine metabolism. Just to mention a few key concepts: post-transcriptional, translational, and post-translational mechanisms; modulation of cytokine receptors; indirect effects that occur as a result of the extensive interactions among various cytokines.

The chapter written by John Kirwan is worth reading for the rheumatologist, as it deals with the clinical aspect of the systemic administration of glucocorticoids in chronic inflammatory arthritis typified by rheumatoid arthritis (RA), in vasculitic episodes typified by those in systemic lupus erythematosus, and in polyarthritis rheumatica and temporal arteritis. It is clearly written, because it questions apparently known facts, especially taking the example of RA. The important very short term anti-inflammatory effects are accepted and are broadly exploited. But is the risk/benefit potential also positive for medium and long term treatment? Do the glucocorticoids perhaps have a much more fundamental influence on the development and progression of RA than previously thought? Is there a differentiated and even treatment-time-dependent influence on synovitis, on the one hand, and on radiological progression, on the other? Possible answers to these exciting questions will not be anticipated here. However, this chapter, in particular, can be recommended, broadening as it does our picture of reality that is sometimes restricted to standard viewpoints.

The non-expert in the field might have wished for a little more clarity occasionally in the illustrations. The references to the individual chapters take into account publications up to and including the year 2000. Overall, this is a good example of how knowledge on established drugs such as the glucocorticoids can be clearly updated.

F Buttgereit

FORTHCOMING EVENTS

Tenth Intensive Applied Epidemiology Course for Rheumatologists
11–15 Mar 2002; Manchester, UK
No previous experience in epidemiology is needed. The course is residential and limited to 25 places
Contact: Ms Lisa McClair, ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK
Tel: +44 (0)161 275 5993
Fax: +44 (0)161 275 5943
Email: Lisa@fs1.sert.man.ac.uk

OMERACT VI
11–14 Apr 2002; Brisbane, Queensland, Australia
Includes two modules: MRI and economics; and five workshops: patients’ perceptions, imaging (healing), progressive systemic sclerosis, mean clinical important difference, and osteoarthritis
Contact: Conference Organisers Q2Q, 7 Swan Street, Old Iswoorth, Middlesex TW7 6RJ, UK
Fax: +44 20 8569 9555
Email: q2q@q2q.co.uk

British Society for Rheumatology XIXth AGM
23–26 Apr 2002; Brighton, UK
Contact: BSR, 41 Eagle Street, London WC1R 4TL, UK
Website: www.rheumatology.org.uk

4th EULAR Sonography Course
25–28 April 2002; Madrid, Spain
The course is entitled “Practical use of musculoskeletal ultrasonography”
Contact: Esperanza Naredo
Email: enaredo@eresmas.com
Website: www.eular.org/courses and www.sameint.it/eular

10th International Vasculitis and ANCA Workshop
25–28 Apr 2002; Cleveland, Ohio, USA
Contact: Debora J Bork, The Cleveland Clinic Foundation, Desk A50, Center for Vasculitis Care and Research, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Tel: 216 445 3353
Fax: 216 445 7569
Email: borkdj@ccf.org
Website for registration and abstract submission: www.clevelandclinicmeded.com/courses/Vasculitis2002.asp

International Congress: New Trends in Osteoarthritis
9–11 May 2002; Milan, Italy
Contact: Organising Secretariat, O.I.C. S.r.l., Via Fatebenefratelli 19, 20121 Milan, Italy
Tel: +39 02 65 71 200
Fax: +39 02 65 71 270
Email: osteoarthritis@oic.it

IOF World Congress on Osteoporosis
10–14 May 2002; Lisbon, Portugal
Contact: IOF Secretariat, 71 cours Albert Thomas, F-69003 Lyon, France
Tel: +33 472 91 41 77
Fax: +33 472 36 90 52
Email: info@iofy.org
Website: www.osteofound.org

5th European Conference on Systemic Lupus Erythematosus
26–30 May 2002; Athens, Greece
Chairman Professor HM Moutsopoulos
Secretariat: Amphitrition Congress Organising Bureau
Email: amphimoutspod@med.uoa.gr
Website: congress@amphrition.gr

Annual European Congress of Rheumatology
12–15 June 2002; Stockholm, Sweden
Contact: Fred Wyss, Executive Secretary EULAR, Wiktorssonstrasse 15, CH-8032, Zurich, Switzerland
Tel: +41 1 583 9690
Fax: +41 1 383 9810
Email: eular@bluewin.ch
Website: www.eular.org

10th International Congress on Behçet’s Disease
27–29 June 2002; Berlin, Germany
Under the auspices of the International Society for Behçet’s Disease
Up to eight young investigator awards, each of $500 will be awarded on the basis of abstracts submitted
Contact: Professor Ch C Zouboulis, Department of Dermatology, University Medical Centre Benjamin Franklin, The Free University of Berlin, Fabeckstrasse 60–62, 14195 Berlin, Germany
Fax: 49 30 84456908
Email: zoubbere@zedat.fu-berlin.de
Website: www.tempel.de/zoubbere
15SD website: www.behcet.ws

29th Scandinavian Congress of Rheumatology
15–18 Aug 2002; Tromso, Norway
Contact: Hans Nossent, Department of Rheumatology, University Hospital Tromso, Norway
Tel: 47 776 27294
Fax: 47 776 27258
Email: 29cr2002@rit.no or revhan@rit.no

Translational Research in Autoimmunity
21–22 Sep 2002; Pavia, Italy
Contact: Organising secretariat: eventi S.R.L., Corso Cavour, 18/20 - 27100 Pavia, Italy
Email: trae@e20pr.com
Website: www.e20pr.com
Congress website: www.medicine.ucsd.edu/albany/2001 meeting

OsteoArthritis Research Society International (OARSI) World Congress
22–25 Sep 2002; Sydney, Australia
Contact: OsteoArthritis Research Society International (OARSI), 205 M Street, NW, Suite 800, Washington DC 20036, USA
Tel: +1 202 367 1177

www.annrheumdis.com
10th International Congress on Antiphospholipid Antibodies

29 Sep–3 Oct 2002; Sicily, Italy
Deadline for abstracts 1 April 2002
Contact: Secretariat, 10th International Congress on Antiphospholipid Antibodies, c/o Kenes International, PO Box 50006, Tel Aviv 61500, Israel
Tel: 972 3 5140018/9
Fax: 972 3 5140077 or 972 3 5172484
Email: aps@kenes.com
Website: www.kenes.com/aps

Third International Congress on Spondyloarthropathies

2–5 Oct 2002; Gent, Belgium
Topics covered will be:
- Innate immunity
- Genetics and HLA-B27
- Animal models and pathogenesis
- Clinical research and therapy
Deadline for abstract submission 31 March 2002
Contact: Organisation and secretariat, Medicongress, Waalpoel 28–34, B-9960 Assenede, Belgium
Tel: +32 9 344 39 59
Fax: +32 9 344 40 10
Email: congresses@medicongress.com
Website: www.medicongress.com

7th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases

14–17 Oct 2002; Nashville, Tennessee, USA
Contact: Lawrence J Marnett, Biochemistry Department, Vanderbilt University, School of Medicine, Nashville TN 37232-0146, USA
Tel: (615) 343 7329
Fax: (615) 343 7534
Website: www.eicosanoids.science.ewayne.edu

66th American College of Rheumatology AGM

25–29 Oct 2002; New Orleans, USA
Contact: ACR, Ronald F Olejko, Director of Conferences and Meetings, 1800 Century Place, Suite 250, Atlanta, Georgia 30045–4300, USA
Tel: +1 404 633 3777
Fax: +1 404 633 1870
Email: acr@rheumatology.org
Website: www.rheumatology.org

Third International Meeting on Social and Economic Aspects of Osteoporosis and Osteoarthritis

7–9 November, 2002; Barcelona, Spain
Contact: Yolande Piette Communication, Boul- evard Kleyer 108, 4000 Liège, Belgium
Tel: 32 4 254 12 25
Fax: 32 4 254 12 90
Email: ypc@compuserve.com

Certifying Examination in Pediatric Rheumatology

18 Nov 2002
Contact: American Board of Pediatrics, 111 Silver Court, Chapel Hill, NC 27514-1513, USA
Tel: 919 929 0461
Fax: 919 918 7114 or 919 929 9255
Website: www.abp.org

Future EULAR congresses

18–21 June 2003; EULAR 2003 Lisbon, Portugal
9–12 June 2004; EULAR 2004 Berlin, Germany
8–11 June 2005; EULAR 2005 Vienna, Austria
21–24 June 2006; EULAR 2006 Amsterdam, The Netherlands

If you have a burning desire to respond to a paper published in the Annals of the Rheumatic Diseases, why not make use of our “rapid response” option? Log on to our website (www.annrheumdis.com), find the paper that interests you, and send your response via email by clicking on the “eLetters” option in the box at the top right hand corner.
Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eLetters” on our homepage.
The editors will decide as before whether also to publish it in a future paper issue.